MedPath

Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.

Not Applicable
Not yet recruiting
Conditions
Cough
Interventions
Registration Number
NCT05888350
Lead Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Brief Summary

To investigate the value of blood eosinophils, FeNO and total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.

Detailed Description

Chronic cough is a frequent complaint in respiratory specialists clinic. CVA, UACS, EB, GERC and AC are common causes of chronic cough, among whom, CVA, EB and AC can be classified as corticosteroid responsive cough.

To recognize the eosinophilic airway inflammation and assess the response of inhaled corticosteroid, induced sputum analysis is the most widely used examination but not all the subjects can provide an suitable sample of sputum for measurements and it's time-consuming.

Recently, blood eosinophils, FeNO and total IgE were detected to be biomarkers of eosinophilic airway inflammation for asthmatics. However, whether can they predict the response to corticosteroid in chronic cough remains uncertain.

The present prospective, multi-center, randomized placebo-controlled study aims to explore the value of blood eosinophils, FeNO and total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
520
Inclusion Criteria
  1. Age: 18-70 years;
  2. Coughing lasting ≥ 8 weeks;
  3. No abnormality in chest imaging in the past 3 months (or there is abnormality but the investigator judges it not the cause of chronic cough);
  4. FEV1% pred>70%;FEV1/FVC>70%;
  5. VAS≥30 in the past 48 hours;
  6. Non-smokers or patients smoked less than 10 pack-years;
  7. Candidates voluntarily participate in and abide by the relevant regulations of the study, can cooperate with corresponding inspections, follow the follow-up plan, and voluntarily sign written informed consent.
Exclusion Criteria
  1. Patients received inhaled or oral corticosteroids or leukotriene receptor antagonist in previous 4 weeks;
  2. Patients with history of upper respiratory tract infection in the past 8 weeks;
  3. Patients taking angiotensin-converting enzyme inhibitors in previous 8 weeks;
  4. Female subjects who are pregnant, breast-feeding or risk of becoming pregnant during the study;
  5. Combined with a definite history of pulmonary diseases such as bronchiectasis, pulmonary interstitial disease, and pulmonary hypertension. Combined with other serious diseases (such as cardiovascular system diseases, metabolic system diseases, immune system diseases, nervous system diseases, etc.) that may affect the normal process of this study;
  6. Participating in other drug clinical trial projects.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo controlled groupPlaceboParticipant inhales matched placebo 1 puff bid for 4 weeks.
Foster treatment groupBeclometasone Dipropionate and Formoterol Inhalation AerosolParticipant inhales Foster (Inhaled Beclometasone Dipropionate and Formoterol Inhalation Aerosol) 1 puff bid for 4 weeks.
Primary Outcome Measures
NameTimeMethod
The AUC of blood eosinophils, FeNO and total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.the 4th week

The area under the receiver operating curve (AUC) of blood eosinophils in predicting the response to inhaled corticosteroid in patients with chronic cough.

The area under the receiver operating curve (AUC) of FeNO in predicting the response to inhaled corticosteroid in patients with chronic cough.

The area under the receiver operating curve (AUC) of total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.

The optimal cut-off value of blood eosinophils in cells/μL-1 in predicting the response to inhaled corticosteroid in patients with chronic cough.the 4th week

The optimal cut-off value of blood eosinophils in cells/μL-1 in predicting the response to inhaled corticosteroid in patients with chronic cough.

The optimal cut-off value of FeNO in pbb in kU/L in predicting the response to inhaled corticosteroid in patients with chronic cough.the 4th week

The optimal cut-off value of FeNO in pbb in predicting the response to inhaled corticosteroid in patients with chronic cough.

The optimal cut-off value of total IgE in kU/L in predicting the response to inhaled corticosteroid in patients with chronic cough.the 4th week

The optimal cut-off value of total IgE in kU/L in predicting the response to inhaled corticosteroid in patients with chronic cough.

The sensitivity and specificity in percentage of blood eosinophils, FeNO and total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.the 4th week

The sensitivity and specificity in percentage of blood eosinophils in predicting the response to inhaled corticosteroid in patients with chronic cough.

The sensitivity and specificity in percentage of FeNO in predicting the response to inhaled corticosteroid in patients with chronic cough.

The sensitivity and specificity in percentage of total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.

Secondary Outcome Measures
NameTimeMethod
Cough VAS change from baseline to the 4th weekthe 4th week

Cough visual analogue scale (VAS) aims to access the severity of cough, ranging from 0 to 100mm. Higher scores mean a worse outcome.

Clinical characteristics of responders and non-respondersbaseline

Clinical characteristics including gender, age and cough duration would be registered in a specific case report form in baseline.

LCQ change from baseline to the 4th weekthe 4th week

Leicester Cough Questionnaire (LCQ)aims to access the life quality of patients wtih chronic cough, ranging from 19 to 133. Higher scores mean a better outcome.

Trial Locations

Locations (1)

The First Affiliated Hospital of Guangzhou Medical University

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath